This article is for providers caring for our members with cancer, rare diseases, and complex conditions
Medzown was founded in 2023 by Jennifer Levin Carter, Founder & CEO, MD, MPH, MBA. Dr. Carter practiced internal medicine at Mount Auburn Hospital in Cambridge, MA. Since then, she has held a variety of leadership roles across healthcare, technology, and precision medicine.
The rest of Medzown’s dedicated team consists of clinical and scientific leaders, trained Navigators, and data and technology experts. You can learn more about them and their mission here.
We’re excited to announce that starting March 1, 2026, Blue Cross is partnering with Medzown*, an independent company, to help patients with cancer, rare diseases, and complex conditions navigate and get timely access to clinical trials.
Medzown’s multi-disciplinary team of Precision Medicine Scientists uses advanced analytics and scientific expertise to prioritize clinical trial options based on a patient’s unique clinical profile.
Medzown can help eligible patients with personalized navigation through clinical trial options based on their medical history and diagnosis, all in collaboration with their existing care team.
Medzown can help you by reducing your administrative burden, including streamlining the research, prior authorization, and enrollment processes required for clinical trials. Medzown provides precision medicine research, not treatment recommendations. They will share their insights and clinical trial reports with you—with the patient's permission—to ensure coordinated care.
Eligible members include fully insured commercial and Medicare Advantage members who have cancer, a rare disease, or a complex condition and:
- Who are not sure about their next treatment option, or
- Their disease is progressing on current treatment, or
- Have failed standard of care or no standard of care is available to them
Starting mid-March, we will notify eligible members about their access to Medzown. Participation is entirely voluntary and included as part of an eligible member’s health plan at no additional cost.
If your patient is interested:
- Patients who are interested in the program can call Medzown at 1-617-468-4043 or send an email to navigators@medzown.com.
- With the patient’s permission, Medzown will share its precision medicine research, actionable insights, and relevant clinical trial options with the patient's existing care team to support shared decision-making.
- A dedicated Medzown Navigator will act as an extension of their existing care team to manage communication and help with enrollment.
*Medzown is not affiliated with any cancer centers or companies. While they work closely with leading cancer centers, they are independent and do not have a vested interest in research.
MPC_10242501Q-2